Docetaxel: promising and novel combinations in ovarian cancer.

about

SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer.Novel hydrophilic docetaxel (CQMU-0519) analogue inhibits proliferation and induces apoptosis in human A549 lung, SKVO3 ovarian and MCF7 breast carcinoma cell lines.

P2860

Q36613447-55ADB623-27CB-4980-94AB-9A5B1DD1BCC8 Q39336275-3659A85C-7209-4234-AF12-D4C3E5246381

P2860

Docetaxel: promising and novel combinations in ovarian cancer.

Item

http://www.wikidata.org/entity/Q35602190

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Docetaxel: promising and novel combinations in ovarian cancer.

@ast

Docetaxel: promising and novel combinations in ovarian cancer.

@en

type

Item

label

Docetaxel: promising and novel combinations in ovarian cancer.

@ast

Docetaxel: promising and novel combinations in ovarian cancer.

@en

prefLabel

Docetaxel: promising and novel combinations in ovarian cancer.

@ast

Docetaxel: promising and novel combinations in ovarian cancer.

@en

P1476

Docetaxel: promising and novel combinations in ovarian cancer.

@en

P2093

J U Mäenpää

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer.

A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.

Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.

Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.

Taxane/platinum/anthracycline combination therapy in advanced epithelial ovarian cancer.

Future directions for the management of ovarian cancer.

Docetaxel: an alternative taxane in ovarian cancer.

Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies.

A dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancer.

Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum.

P2888

sj.bjc.6601498

P304

S29-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1038/SJ.BJC.6601498

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

89 Suppl 3

http://www.w3.org/2001/XMLSchema#string

P577

2003-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8971742

http://www.w3.org/2001/XMLSchema#string

P6179

1020171992

http://www.w3.org/2001/XMLSchema#string

P698

14661044

http://www.w3.org/2001/XMLSchema#string

P921

ovarian neoplasm

ovarian cancer

hydrocarbon

P932

2750617

http://www.w3.org/2001/XMLSchema#string

Docetaxel: promising and novel combinations in ovarian cancer.

about

P2860

P2860

Docetaxel: promising and novel combinations in ovarian cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P577

P5875

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P577

P5875

P6179

P698

P921

P932